Last reviewed · How we verify
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 49 |
| Start date | Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Nov 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Esophageal Cancer
- Gastric Adenocarcinoma
- HER2 Gene Mutation
Interventions
- Pembrolizumab
- Trastuzumab
- Oxaliplatin
- Capecitabine
- 5-Fluorouracil
- Docetaxel
Countries
United States